UPDATE 1-UK cost agency queries value of $700,000-a-year Alexion drug


An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said. Kanuma is designed for treating lysosomal acid lipase deficiency, a rare inherited genetic disease in which fats build up in cells.



from Biotech News